In a development that could reshape cancer treatment, Moderna and Merck announced that their personalized mRNA vaccine, intismeran, succeeded in a late‑stage trial when paired with the immunotherapy Keytruda. The interim data showed the regimen met its primary endpoint of lowering cancer recurrence and also achieved its secondary goal of limiting metastasis.
Trial design and results
The study enrolled 1,137 patients with stage 2b to stage 4 melanoma who had undergone surgical removal of their tumors. Participants were randomly assigned to receive up to nine doses of Keytruda plus the custom‑made vaccine, or Keytruda alone, over roughly a year. Researchers reported no new safety signals; previously observed side effects included fatigue, injection‑site pain and chills.
Interim analysis indicated a statistically significant reduction in recurrence compared with the control arm. Earlier, in January, a mid‑stage trial of the same combination showed a 49% reduction in the risk of recurrence or death after five years.
What the vaccine is
Intismeran is a personalized mRNA vaccine created from an analysis of each patient’s tumor mutations. The vaccine delivers genetic instructions that prompt the body’s cells to produce proteins unique to the patient’s cancer, training the immune system to recognize and attack any remaining malignant cells. When combined with Keytruda, a checkpoint inhibitor that releases the brakes on immune response, the approach aims to provide a two‑pronged attack on melanoma.
Company statements and next steps
Moderna CEO Stéphane Bancel called the results “as big a day for humanity as Nov. 16, 2020,” referencing the company’s pivotal COVID‑19 vaccine announcement. He added that the success moves the long‑standing goal of individualized mRNA cancer therapy closer to reality. Both companies said they intend to file for regulatory approval within months, though no specific timeline was given.
Key industry observers noted the data could serve as a catalyst for further mRNA oncology research and potentially boost investor confidence in Moderna, whose stock surged 160% on the news.
Broader context
Melanoma remains the deadliest form of skin cancer, with more than 1.5 million Americans living with the disease in 2023, according to the National Cancer Institute. While mRNA technology gained public attention during the COVID‑19 pandemic, it has also faced criticism and misinformation regarding safety. Experts continue to affirm that the technology’s safety profile is well‑understood, and the current trial reported no unexpected adverse events.
Government funding for mRNA research has fluctuated in recent years. The U.S. Department of Health and Human Services cancelled a $590 million contract with Moderna for an mRNA flu vaccine and later ended funding for multiple mRNA projects through the Biomedical Advanced Research and Development Authority. Nonetheless, the FDA recently approved Moderna’s mRNA‑based flu vaccine, indicating regulatory willingness to evaluate such products.
Implications for patients
If approved, the vaccine could become the first personalized mRNA cancer therapy available in the United States, offering a new option for patients at high risk of melanoma recurrence. The treatment’s success may also encourage similar approaches for other solid‑tumor cancers, a prospect highlighted by Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy.
Moderna and Merck plan to present the full data at an upcoming medical conference and share it with regulators in the near future.
Original reporting: KRDO (Colorado Springs metro) — read the source article.
